Neutralizing Antibody Response to the AreXvy Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients: Assessment Against Reference and Seasonal Strains

Neutralizing Antibody Response to the AreXvy Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients: Assessment Against Reference and Seasonal Strains

Background: Respiratory Syncytial Virus (RSV) is a significant cause of morbidity and mortality among lung transplant (LTx) recipients. Therapeutic options are limited, emphasizing the importance of prevention. The Arexvy<sup>®</sup> vaccine (RSVPreF3) showed promising efficacy among imm...

Full description

Saved in:
Bibliographic Details
Main Authors: Liran Levy, Dafna Yahav, Mark Benzimra, Yael Bezalel, Tomer Hoffman, Neta Shirin, Tomer Sinai, Menucha Jurkowicz, Ofir Deri, Noa Matalon, Milton Saute, Yaniv Lustig, Eyal Nachum, Michael Peled, Ital Nemet, Michal Mandelboim
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Vaccines
Subjects:
respiratory syncytial virus (RSV)
Arexvy
vaccine
lung transplant
immunogenicity
Online Access:https://www.mdpi.com/2076-393X/13/4/398
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2076-393X/13/4/398

Similar Items